Background: Cell-size-control systems, coupled with apoptotic-and cell-proliferation-regulatory mechanisms, determine the overall dimensions of organs and organisms, and their dysregulation can lead to tumor formation. The interrelationship between cell-growth-regulatory mechanisms and apoptosis during normal development and cancer is not understood. The TRK-fused gene (TFG) promotes tumorigenesis when present in chromosomal rearrangements from various human-cancer types by unknown mechanisms. Apaf1/CED-4 is essential for apoptosis but has not been shown to function in cell-growth control. Results: We found that loss of TFG-1, the TFG ortholog in Caenorhabditis elegans, results in supernumerary apoptotic corpses, whereas its overexpression is sufficient to inhibit developmentally programmed cell death. TFG-1 is also required for cells and nuclei to grow to normal size. Furthermore, we found that CED-4 is required for cell-growth inhibition in animals lacking TFG-1. However, caspases, the downstream effectors of CED-4-mediated apoptosis, are not required in TFG-1-or CED-4-regulated cell-size control. CED-4 acts to inhibit cell growth by antagonizing the effects of other conserved cell-size-regulating proteins, including cAMP response element binding (CREB) protein, translation-initiation factor eIF2B, and the nucleolar p53-interacting protein nucleostemin. Conclusions: These findings show that TFG-1 suppresses apoptosis and is essential for normal cell-size control, suggesting that abnormalities in the cell-growth-promoting and apoptosis-inhibiting functions of TFG might be responsible for its action in tumorigenesis. Also, they reveal that CED-4 plays a pivotal role in activating apoptosis and restricting cell and nuclear size, thereby determining the appropriate overall size of an animal. Thus, these findings reveal links between the control mechanisms for apoptosis and cell growth.
Introduction
Cells actively modulate growth parameters to achieve reproducible dimensions appropriate to their functions. Cell-sizecontrol systems, coupled with regulatory mechanisms for apoptotic cell death and cell proliferation, determine the overall dimensions of organs and organisms, and dysregulation of these processes can lead to cancer. Apoptosis and cell size are controlled by largely distinct molecular-regulatory events.
The pathways regulating apoptosis are highly conserved among animals. The core apoptotic-regulatory pathway in C. elegans consists of four proteins (CED-3, CED-4, CED-9, and EGL-1) that are critical for the switch between cell survival and apoptosis [1] . CED-3, a member of the caspase family of cysteine proteases and the main executor of apoptosis, is triggered to undergo autoproteolytic activation into its proapoptotic form by CED-4, an ortholog of mammalian Apaf-1. CED-9, the worm equivalent of mammalian proto-oncoprotein Bcl-2, promotes cell survival by binding to CED-4 and preventing it from activating CED-3. In cells fated to undergo apoptosis, the anti-apoptotic activity of CED-9 is blocked by EGL-1, a BH3-only-domain protein.
In contrast to apoptosis, several independent mechanisms appear to regulate cell size. The best-understood mechanism controlling cell and body size in C. elegans is the Sma/Mab pathway, involving members of the TGF-b superfamily and their transducers [2] . Smads encoded by sma-2, sma-3, and sma-4 transduce TGF-b signals into the nucleus and regulate cell and body size through transcriptional regulation of lon-1 and other downstream factors. The Sma/Mab pathway is negatively regulated by LON-2, a member of the glypican family [3] . Epistasis studies have shown that LON-2 functions upstream of the Sma/Mab pathway, as mutations in lon-2 produce long animals only when the TGF-b ligand DBL-1 and the TGF-b receptor SMA-6 are intact [3] . A number of other cell-size-regulatory mechanisms exist, including the insulin/ insulin-like growth factor (IGF)-and target of Rapamycin (TOR)-signaling pathways [4] ; however, their roles in cell-size regulation in C. elegans are less defined.
Though the control of cell growth and apoptosis must be coordinated, little is known about how this is achieved. We have found that the essential apoptotic regulator, ced-4, and the C. elegans ortholog of the human TFG proto-oncogene participate in both cell-size control and apoptosis, suggesting that they link these two processes. The human TFG gene was identified from chromosomal rearrangements in a variety of malignant tumor types, including papillary thyroid carcinomas, anaplastic large cell lymphomas, and extraskeletal myxoid chondrosarcomas [5] [6] [7] [8] (Figure 1A ). All resulting protein chimeras contain an in-frame fusion of TFG at the amino-terminus, and some have been shown to possess oncogenic activity [5, 7, 9] . The TFG portion of the oncogenic-fusion form is essential for this transforming activity, as well as for interactions with other proteins [10] [11] [12] [13] . TFG is upregulated in response to TALL-1 [14] , a member of the tumor-necrosis-factor family implicated in B cell proliferation and autoimmunity. TFG was recently reported to interact with PTEN [15] , a key tumor suppressor that modulates cell growth, division, and death. These findings raise the possibility that TFG might contribute to cancer by regulating such cellular activities.
We report here that the single TFG ortholog in C. elegans, tfg-1 [16] (Figure 1A) , both suppresses apoptotic cell death and activates cell and nuclear growth by a pathway that is apparently independent of TGF-b-and insulin-signaling pathways. The reduced cell and nuclear size seen in the absence of TFG requires CED-4 function, implicating CED-4 in cell growth inhibition in addition to its proapoptotic action.
Moreover, we found that three other proteins whose functions are required for normal cell and body size are also antagonized by CED-4, suggesting that CED-4 performs a general role in restriction of cell growth and body size. Thus, CED-4 might provide a mechanism for coordinating the processes of cell death and cell growth/cell-size control.
Results

TFG-1 Regulates Apoptotic Cell Death
To evaluate the tfg-1 gene's possible role in growth, proliferation, and apoptosis, we investigated its function in C. elegans. We found that inactivation of tfg-1 by RNAi results in a significant increase in the number of apoptotic corpses during embryogenesis ( Figure 1B) . At the ''comma'' stage of embryogenesis, when much programmed cell death occurs, tfg-1(RNAi) embryos contain an average of 12.6 6 2.8 corpses, significantly higher than the number in control wild-type embryos (8.5 6 2.7 corpses; Wilcoxon rank sum, p = 2.98 3 10 26 ). A similar elevation in cell-corpse number is also seen in a cell-corpse-engulfment-defective ced-1(e1735) mutant ( Figure S1A , available online). This elevated cell death was blocked by mutations in the core cell-death pathway (data not shown), indicating that most cell death in tfg-1(RNAi) worms relies on the canonical CED-3, CED-4-dependent celldeath pathway. However, later in development, some cells undergo CED-3-independent death in tfg-1(RNAi) animals (Table S1 ). Such CED-4-dependent, CED-3-independent apoptosis has also been reported with the ICD-1 cell-death suppressor [17] .
Localization of TFG-1 is consistent with a role in apoptosis: immunoreactive TFG-1 is detectable as early as the two cell stage of embryogenesis, and its expression continues throughout embryogenesis (e.g., Figure 2 ). Closer examination of the subcellular localization of TFG-1 revealed a punctuated staining pattern in the cytoplasm, which partially colocalizes with mitochondrial COX1 (Figures 2D-2F ). Given that mitochondria are key sites for apoptotic regulators [1] , the partial mitochondrial localization of TFG-1 and the tfg-1(RNAi) phenotype are suggestive of a possible anti-apoptotic action in this organelle.
The elevation in cell-corpse number in tfg-1(RNAi) animals results from either inappropriate cell death or reduced engulfment of cell corpses. To further assess the role of tfg-1 in apoptotic regulation, we asked whether its overexpression is sufficient to suppress developmentally programmed cell death by driving it ubiquitously under the control of a heatshock promoter (Figure 1 ). Embryos overexpressing TFG-1 contain significantly fewer cell corpses at the comma stage (average of 4.1 6 1.9) than do the non-heat-shocked controls (6.9 6 1.9, Wilcoxon rank sum, p = 1 3 10 26 , Figure 1C ). This decrease in cell-corpse number reflects bona fide suppression of the apoptotic pathway, given that we observed extra surviving cells in the anterior pharynx of the resulting larvae in the same positions as the extra survivors in mutants defective for essential pro-apoptotic genes ( Figure S1B ). Thus, TFG-1 is sufficient, and may be necessary, to inhibit the normal apoptotic pathway.
TFG-1 is Required to Regulate Normal Nuclear, Cell, and Body Size
The temporal flexibility of gene inactivation by RNAi provides an opportunity for the study of functions of essential genes that might otherwise be masked by lethality. We found that although elimination of TFG-1 from embryos results in lethality prior to hatching, removal of all detectable TFG-1 by RNAi from developing larvae that had expressed it at normal levels during embryogenesis does not prevent growth to adulthood. However, such worms are much smaller than their wild-type counterparts (Figures 3A and 3B; average length 0.73 6 0.13 mm versus 1.34 6 0.1 mm, respectively), revealing that TFG-1 is required during postembryonic development for the regulation of body size. Body and organ size in animals is a function of total cell number and individual cell size. Given that TFG-1 suppresses cell death, the reduced size of tfg-1(RNAi) worms might be a consequence of decreased cell number as a result of cell loss through increased apoptosis. This was not the case: we found that the total number of DAPI-stained somatic nuclei quantifiable in tfg-1(RNAi) worms was not significantly different from that in wild-type (938.7 6 44.7, n = 27 and 941.3 6 43.6, n = 25, respectively; see Table 1 ). In contrast, we found that the average size of both locomotory muscle cells and epidermal cells, as well as their respective nuclei, is dramatically reduced in tfg-1(RNAi) adult worms compared to wild-type ( Figure 3C , Table 1 , and not shown). The reduction in cell size accounts for the reduced body size in these animals. Thus, TFG-1 influences body size primarily by controlling the overall dimensions of individual cells. Cell size is determined by the combined action of two opposing processes, cell growth and cell division. The number of muscle cells in adult tfg-1(RNAi) worms is normal ( Table 1 ), suggesting that TFG-1 does not affect cell division. During postembryonic development, all but one of the lateral epidermal (seam) cells divide during each larval stage [18] . This invariant cell-division pattern provides a useful tool to further distinguish the influence of TFG-1 on cell division versus growth. By examining a marker of apical junctions surrounding epithelial cells [19] , we found that seam cells undergo a similar division pattern in tfg-1(RNAi) larvae as in wild-type, through the molt to adulthood, confirming that TFG-1 does not alter the number of cell divisions. In contrast, we found that seam cells are substantially growth-inhibited in tfg-1(RNAi) worms starting at the L3 stage, demonstrating that TFG-1 is a novel regulator of cell growth and size. This is apparent from a decrease in the longitudinal dimension of the seam cells ( Figure 3D ). This effect is particularly dramatic by the end of development: the body volume and volume of the diminutive cells in tfg-1(RNAi) adults are only w30% those of wild-type cells. Thus, TFG-1 is largely responsible for determining the size of adult worms.
The small locomotory muscle cells in tfg-1(RNAi) worms also contain smaller nuclei (Table 1) , prompting us to examine whether DNA content is reduced in nuclei of TFG-1-depleted worms. A change in DNA content is often associated with an alteration in nuclear volume and cell size: for example, the large size of intestinal cells in worms is accompanied by increased DNA ploidy of up to 32 N as a result of endoreduplication [20] . Moreover, somatic ploidy has recently been shown to be causally linked to body size in C. elegans [21] . Nevertheless, ploidy is only one factor underlying cell-and nuclear-size changes: many cells of dramatically different sizes remain diploid throughout life, and mutants with small body size but with the same ploidy as wild-type have been reported [21] . We found no significant difference in the average ploidy of intestinal cells between dwarf tfg-1(RNAi) and control animals (30.4N 6 6.6, n = 26 versus 31.7N 6 3.7, n = 22, respectively; Student's t test, p = 0.41; Figure 4A ). In addition, we observed that epidermal nuclei, which also undergo larval endoreduplication, contained a similar DNA content in tfg-1(RNAi) and wild-type adults (7.4N 6 2.3, n = 26 versus 8.4N 6 1.6, n = 22, respectively; Student's t test, p = 0.1). Thus, differences in nuclear DNA content cannot explain the dramatic effect of TFG-1 on the dimensions of nuclei and cells. We then tested for possible genetic interactions between TFG-1 and other cell-size-regulatory pathways. We found that inactivation of TFG-1 in sma-3 and sma-4 mutant animals additively reduced body size ( Figure 4B) , implying that the TGF-b pathway and TFG-1 act in parallel to control cell size. Similarly, the elongated body phenotype resulting from a mutation in lon-2 is suppressed by tfg-1(RNAi) in a simple additive relationship ( Figure 4B ), implying that TFG-1 and LON-2 act independently to regulate body size. This contrasts with the strong epistatic relationship between SMA-4 and LON-2, which are believed to act in the same pathway: sma-4(-); lon-2 double mutants are as small as sma-4(-) single-mutant animals [22] . Mutations that disrupt IGF-or TOR-signaling pathways also showed no conspicuous interactions with TFG-1 related to cell-size phenotype (not shown). Human tumor suppressor PTEN [15] , which is known to regulate cell size, interacts with TFG; however, we found that mutations that eliminate the function of worm PTEN, DAF-18, do not alter the cell-size phenotype of tfg-1 (not shown). Thus, TFG-1 apparently functions in a novel pathway independent of TGF-b and insulin signaling to control cell growth and size in C. elegans.
CED-4 Reduces Cell Size in Mutants Lacking TFG-1
Our discovery that TFG-1 functions both to repress apoptosis and to regulate cell size prompted us to ask whether proteins known for their roles in apoptosis might also act in cell-size regulation. We found that key apoptotic factors, CED-3, CED-9, and EGL-1, do not significantly affect the diminutive cell size in tfg-1(RNAi) animals ( Figure 4C , Figure S2 ). In striking contrast, we observed that two strong loss-of-function alleles of ced-4 strongly suppress the cell-size phenotypes of adult tfg-1(RNAi) worms (Figures 5A and 5E ). For example, ced-4(n1162); tfg-1(RNAi) worms (average length 1.01 6 0.12 mm, n = 120) are similar in size to ced-4(n1162) single-mutant animals (average length 1.14 6 0.11 mm, n = 122). Consistent with the restored body size, we found that muscle cells in ced-4(n1162); tfg-1(RNAi) worms are much larger than those in tfg-1(RNAi) worms and are similar in size to muscles in ced-4(n1162) single mutants ( Figure 5B , Table 1 ). ced-4 mutants do not appear to show reduced susceptibility to RNAi [17] . We further confirmed the efficacy of tfg-1 RNAi in the ced-4 mutants: TFG-1 was undetectable in extracts from both tfg-1(RNAi) and ced-4(n1162); tfg-1(RNAi) animals ( Figure 5C ).
The restoration of body and cell dimensions by ced-4 mutations demonstrates that CED-4 not only is necessary to activate the apoptotic program but also functions to limit cellular dimensions. In apoptosis, the ced-4 locus possesses dual functions as both a pro-and anti-apoptotic regulator [23] . A similar dual role in both restricting and promoting cell growth might also exist in CED-4-dependent cell-size regulation, given that we observed that ced-4(-) worms have a slightly smaller body and cell size than do wild-type worms ( Figures  5A and 5D) .
Caspases are the well-documented downstream effectors of CED-4 and Apaf-1 in apoptosis, and the only proteins in C. elegans known to possess caspase activity are CED-3 and CSP-1 [24] . We found that removal of either one or both of these caspases does not alter the small body size of tfg-1 (RNAi) animals ( Figures 4C and 4D ). For example, the average body length of adult ced-3(n717); csp-1(tm917); tfg-1(RNAi) worms (0.74 6 0.13 mm, n = 108) is virtually identical to that of tfg-1(RNAi) worms (0.73 6 0.13 mm, n = 137). Also, we found that ubiquitous high expression of baculovirus p35, a potent pancaspase inhibitor that effectively blocks normal apoptotic death in C. elegans [25] , does not detectably alter the size of tfg-1(RNAi) animals (not shown). These findings indicate that although caspases are critical for CED-4-mediated apoptosis, CED-4 apparently mediates cell-size control independently of caspase function.
Regulation of ribosomal biogenesis and protein synthesis is known to govern cell growth. However, the protein content of some C. elegans mutants with altered body size, including the larger-than-normal egl-4 mutants and diminutive sma-1 mutants, does not change in proportion to their respective body sizes. In these cases, the alteration in body size has been attributed to changes in DNA content or fluid content [26] . In contrast, we observed in tfg-1(RNAi) worms a CED-4-dependent reduction in total protein content that parallels the CED-4-dependent decrease in body and cell size ( Figure 5D ). The strong correlation between body size and protein content suggests that CED-4/TFG-1 probably controls cell and body size through modulation of the protein production and accumulation machinery.
CED-4 Antagonizes the Function of CREB, eIF2B, and nucleostemin in Cell-Size Regulation
Suppression of the diminutive-cell-size phenotype of tfg-1(RNAi) by ced-4 mutations might indicate that CED-4 antagonizes normal cell-size-regulatory mechanisms, or it might instead reflect a specific regulatory relationship between TFG-1 and CED-4. To address this issue, we investigated whether mutants of other cell-size regulators show a CED-4-dependent decrease in cell size. The CREB/ATF family of transcription factors is required for cell growth and survival [27] , and CREB null mice are w30% smaller than their wild-type counterparts [28] . Furthermore, cells expressing a dominant-negative form of CREB are reduced in size [29] . We found that RNAi knockdown of the gene encoding CREB in C. elegans similarly results in a profound decrease in body size ( Figure 6A ) that is even more severe than that seen in tfg-1 mutants. The volume of cells in these mutant adults is, remarkably, only w20% that of wild-type cells. This profound cell-size phenotype was strongly suppressed by a ced-4(n1162) mutation (Figure 6A ), underscoring the broad role of CED-4 in cell-size control.
Factors that mediate translation affect cell size; for example, eIF2B mediates hypertrophic growth of cardiac myocytes [30] . We found that RNAi of the eIF2B-encoding gene, iftb-1, in C. elegans results in a small-body-size phenotype, which is also suppressed by a ced-4 mutation ( Figure 6B) . Thus, the action of CED-4 in limiting cell size extends to regulation of cell growth through a translational regulator. Nucleostemin, a nucleolar GTPase enriched in proliferating stem cells and cancer cells, has been implicated in the regulation of ribosomal assembly [31] . Nucleostemin can physically interact with, and modulate the activity of, the tumor suppressor p53. Loss of nucleostemin results in p53-dependent apoptosis and cell cycle arrest [32, 33] , and its overexpression results in cellcycle arrest and formation of giant cells [34] . We found that knock down of the expression of the worm ortholog of nucleostemin results in a reduced-body-size phenotype that is also suppressed by a ced-4(n1162) mutation ( Figure 6C ).
These observations demonstrate that CED-4 represses cell growth as a result of mutations in several apparently distinct pathways, revealing that it acts broadly to regulate cell and body size.
Discussion
Human TFG is involved in several different cancer types; however, the mechanism of its action in tumorigenesis is unclear. We have found that C. elegans TFG-1 acts as both a novel apoptotic suppressor and an activator of cell growth. These observations help to illuminate the role of human TFG in cancer: the inappropriate activity of oncogenic forms of TFG-1 might promote tumor development by inhibiting the normal cell-death program, which prevents tumor development, while also activating the cell-growth-regulatory machinery. In both of these processes, TFG-1 appears to act antagonistically with CED-4, which is essential for activation of the apoptotic program and for the dramatic reduction of the size of cells when TFG-1 is absent.
CED-4 and its mammalian ortholog, Apaf-1, have been well studied for their critical roles in apoptotic regulation. Both act as adaptor proteins that trigger the activation of downstream caspases, thereby executing the cell-death program. However, several recent studies have demonstrated that CED-4/Apaf-1 has functions in other processes in addition to apoptosis. Apaf-1 mediates DNA-damage-induced cell-cycle arrest at the S phase [35, 36] . This DNA-damage-checkpoint function is conserved between human and worms: loss of CED-4 function leads to a similar cell-cycle-arrest defect in the animal's germline after exposure to g or UVC irradiation [36] . CED-4 has also been found to be required for hypoxic and volatile anesthetic preconditioning in C. elegans [37, 38] . Our finding that CED-4 opposes the cell-size-regulatory action of TFG-1 reveals a new aspect of the nonapoptotic vital functions of CED-4. It is likely that CED-4 performs a general role in the control of body and cell size, given that it also limits the size of cells in animals depleted for three other cell-growthregulating genes. It is interesting to note that C. elegans cells developmentally programmed to die are much smaller than their surviving sisters at the time that they are born [39] . The CED-4 dependence of cell-size control in the adult soma and in cells doomed to die through the developmental program might reflect a related process mediated by this key apoptotic regulator. Thus, some of the cell-death-activating machinery, particularly that involving CED-4, might actively promote this diminutive cell size at the time that a cell has committed to the cell-death pathway. Our results imply that CED-4 is required in many, if not all, cells for regulation of the size of surviving cells that never trigger the apoptotic program.
As with human TFG, CREB appears to be a proto-oncoprotein [40] . Both CREB and PTEN, which interacts with TFG, regulate glucose metabolism and functionally interact: for example, PTEN suppresses cyclin D2 expression and, therefore, cell proliferation in a CREB-dependent manner [41] . We found that RNAi knockdown of either gene in C. elegans leads to a diminutive-body-size phenotype that is suppressed by inactivation of ced-4. Moreover, similar to tfg-1, RNAi knockdown of CREB also leads to an increase in embryonic cell death ( Figure S3 ). These observations suggest that the cell-size-regulatory mechanisms of TFG and the CREB transcription factor might act through related pathways.
It has been suggested that C. elegans cell size is influenced by changes in DNA content, protein synthesis, cell cycle, and/ or metabolism [42] . We found that TFG-1/CED-4-regulated body-and cell-size control is largely independent of nuclear DNA content but highly correlated with total protein level.
This suggests that a possible mechanism for TFG-1/CED-4 function in cell-and body-size regulation is modulation of protein production and accumulation. In support of this notion, we found two additional factors associated with protein synthesis, eIF2B and NST-1, that show CED-4-dependent bodysize regulation.
In summary, our findings related to the function of the protooncogene TFG-1 and the pro-apoptotic factor CED-4 in apoptosis and cell-size regulation suggest a possible link between these two key cellular processes ( Figure 6D ). That CED-4 antagonizes the action of at least four genes that function in apparently distinct processes to regulate body and, presumably, cell size indicates a prominent role of CED-4 in establishing appropriate cell and body size during development.
Experimental Procedures
Cell-Corpse Counts, Total-Somatic-Cell Quantification, and Cell-Size Measurement For cell-corpse counts, L4 animals were fed on either tfg-1(RNAi) or unc-22(RNAi) plates for 20 hr. Developing embryos were then collected from both populations, and the number of cell corpses were determined with the use of Nomarski optics as described elsewhere [43, 44] . For total-somatic-cell quantification, freshly hatched L1 animals were fed on either tfg-1(RNAi) or control L4440 RNAi plates and collected at late L4 stage for fixing with Carnoy's solution and subsequent staining with DAPI (diamidinophenolindole) as described elsewhere [45] . Subsequently, DAPI-stained somatic nuclei were counted with the use of a fluorescent microscope. Strains harboring GFP expression in muscle and seam cells (pmyo-3::mito::GFP and AJM-1::GFP, respectively) were used for cell-size measurement. Embryos were hatched and subjected to either control or tfg-1(RNAi) treatment. At the indicated time points, growing animals were removed and imaged with an Olympus Fluoview500 confocal microscope. Cell size and length in collected images were quantified with NIH Image J software. The volume of the rhomboid-shaped muscle cell was estimated with the equation V = SH, in which S is the maximum cross-sectional area and H is the height/thickness of the cell. All data are reported as mean 6 SD. Body-Length, Body-Volume, and Ploidy Measurements We generated synchronized worm populations by allowing 15 gravid hermaphrodites to lay eggs on control or tfg-1 RNAi plates for 1 hr before removing the adults and allowing eggs to develop. Three-day-old adults that developed from these eggs were photographed on a dissecting scope and analyzed with NIH Image J software. Body volume was calculated, with the assumption that the worm is cylindrical, with the equation V = p(D/2) 2 L, in which D is the body width across the vulva and L is the longitudinal body length. Ploidy was measured as described elsewhere [21] . Images of nuclei were analyzed with NIH Image J software.
Analysis of Protein Contents and Western Blots
Total protein content of 3-day-old adult animals was measured as described elsewhere [26] . Populations of control L4440 RNAi-or tfg-1(RNAi)-treated mixed-stage animals were collected and lysed in sodium dodecyl sulfate (SDS) sample buffer (50 mM Tris-HCl [pH 6.8], 10% glycerol, 2% SDS, 0.5% b-mercaptoethanol, 0.04% Bromphenol Blue). Samples were separated by 10% SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. Blots were probed with antibodies against TFG-1 for the endogenous TFG-1 level in control or tfg-1(RNAi)-treated worms. Anti-actin blots were used as an internal loading control.
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